| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 29.40K | 17.40K | 199.23K | -8.34M | 6.10M | 2.14M |
| Gross Profit | 29.40K | 17.40K | 199.23K | 66.01K | 63.78K | 151.16K |
| EBITDA | -1.13M | -1.18M | -12.67M | -10.25M | 0.00 | 0.00 |
| Net Income | -2.07M | -3.77M | -12.61M | -10.45M | 4.58M | 803.89K |
Balance Sheet | ||||||
| Total Assets | 10.94M | 11.31M | 13.15M | 25.18M | 32.76M | 24.30M |
| Cash, Cash Equivalents and Short-Term Investments | 74.00K | 382.21K | 297.56K | 931.76K | 1.96M | 2.13M |
| Total Debt | 170.00K | 161.11K | 418.20K | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 655.00K | 597.62K | 848.44K | 325.00K | 342.06K | 295.60K |
| Stockholders Equity | 10.29M | 10.71M | 12.30M | 24.85M | 32.42M | 24.00M |
Cash Flow | ||||||
| Free Cash Flow | -1.16M | -1.57M | -1.22M | -2.20M | -1.48M | -1.19M |
| Operating Cash Flow | -1.16M | -1.57M | -1.22M | -2.20M | -1.48M | -1.19M |
| Investing Cash Flow | -442.39K | -406.39K | 151.92K | -1.63M | -2.50M | -1.86M |
| Financing Cash Flow | 1.55M | 1.65M | 431.54K | 2.80M | 3.81M | 4.17M |
Tern Plc has announced an update regarding its capital commitment to Sure Valley Ventures Enterprise Capital Fund LP (SVV2). The company has invested approximately £1.3 million into SVV2 but faces challenges in meeting further capital calls due to insufficient funds and limited access to future funding. As a result, Tern has requested relief from its funding obligations, leading to its classification as a ‘defaulting investor’ under the SVV2 Limited Partnership Agreement. This status may affect Tern’s rights to distributions and recovery compared to non-defaulting investors. Despite these challenges, Tern aims to maintain its focus on protecting shareholder interests and long-term value creation from its key portfolio companies.
Tern Plc has announced the extension of the maturity dates for approximately £0.3 million of convertible loan notes in Talking Medicines Limited to 21 November 2029. This strategic move is expected to enhance Tern’s negotiating position for a potential exit from its investment in Talking Medicines, aligning the terms of the loan notes with previous agreements.
Tern plc announced that its total issued ordinary share capital consists of 672,713,705 Ordinary Shares, each with one voting right, and none held in Treasury. This information is crucial for shareholders to determine their notification requirements under the FCA’s Disclosure Guidance and Transparency Rules.
Tern plc announced the results of its Open Offer, which closed on 14 October 2025, resulting in the issuance of 30,227,239 new Ordinary Shares and raising approximately £151,136. This move follows the failure to pass a resolution at the company’s AGM to issue new shares without pre-emption rights. The company is also implementing cost-saving measures, including a 50% salary reduction for directors and executive managers, to extend its cash runway into Q1 2026. Tern is exploring alternative funding solutions to meet its financial requirements, which may involve more costly or dilutive options.
Tern Plc has announced a reduction in the fixed remuneration for its board and executive management, alongside a commitment to distribute proceeds from successful exits of its investments. This move aims to align management and shareholder interests, with a 50% salary cut for key executives and a new performance-aligned remuneration policy. The company is focused on maximizing returns from its portfolio while maintaining strict cost controls, and shareholders are promised a distribution of at least 50% of net proceeds from any investment exit over £1 million.
Tern Plc has announced an Open Offer to raise up to £642,486 by issuing up to 128,497,293 Open Offer Shares at a price of 0.50p per share. This initiative is aimed at providing existing shareholders the opportunity to participate proportionally to their current holdings. The company is not underwriting the offer, and the shares are expected to commence trading on AIM on 16 October 2025. The move comes as Tern Plc continues to focus on cost control and operational efficiency amidst a challenging macroeconomic environment for early-stage technology businesses. The company is optimistic about the progress of its portfolio companies, although it acknowledges that immediate exit opportunities may not be favorable.
Tern Plc has announced an extension of its loan facility term to preserve cash resources and enhance negotiating flexibility for potential capital requirements of its investments. The repayment date of the loan has been extended to 5 March 2026, with approximately £150,000 remaining outstanding, accruing interest at 1.00% per month.